ContraFect Corp.
(NASDAQ : CFRX)

( )
CFRX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
VTLVital Therapies, Inc.
1.50%13.513.3%$792.68m
AMGNAmgen Inc.
0.61%205.261.3%$754.03m
GILDGilead Sciences, Inc.
0.89%63.700.9%$387.63m
CELGCelgene Corporation
0.27%95.001.3%$361.73m
ILMNIllumina, Inc.
1.34%290.013.5%$325.50m
BIIBBiogen Inc.
0.57%233.001.3%$307.07m
VRTXVertex Pharmaceuticals Incorporated
2.11%184.941.9%$260.38m
EXASExact Sciences Corporation
0.99%121.0024.1%$248.23m
ALXNAlexion Pharmaceuticals, Inc.
1.66%110.852.0%$238.74m
REGNRegeneron Pharmaceuticals, Inc.
1.28%296.852.6%$212.35m
AAgilent Technologies, Inc.
2.18%71.111.6%$206.33m
SRPTSarepta Therapeutics, Inc.
2.44%124.9514.7%$156.17m
INCYIncyte Corporation
3.11%83.122.5%$97.22m
BMRNBioMarin Pharmaceutical Inc.
6.65%76.504.3%$91.98m
SGENSeattle Genetics, Inc.
3.25%79.206.5%$90.21m

Company Profile

ContraFect Corp. is a clinical stage biotechnology company , which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.